Clinical trials: Non Organic Psychosis
Schizophrenia Disorders
Investigating the Effect of Diroximel Fumarate on Glutathione in Schizophrenia
Schizophrenia is a condition that causes symptoms like delusions, hallucinations, reduced motivation and muddled thinking. It is a common, severe and disabling psychiatric illness affecting about 1/100 (1%) of people.
- Trial name
- FORTUNE (NCT06957808)
- Testing
- Diroximel fumarate (DRF)
- Where
- 3 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- King's College London
Psychosis
Computer-Aided Learning for Managing Stress
The purpose of this study is to learn whether a new family therapy using computer games with biofeedback might help people at clinical high risk for psychosis and their family members learn to experience less stress and have…
- Trial name
- CALMS (NCT02531243)
- Testing
- CALMS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Beth Israel Deaconess Medical Center
First-episode Psychosis
HIIT in Patients With a First-episode Psychosis
This study aims to estimate the effect of a 3-month High Intensity Interval Training on antipsychotic-induced weight gain in patients with a first episode of psychosis, as well as to determine whether these effects are maintained…
- Trial name
- NCT04792476
- Testing
- High Intensity Interval Training
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Intervención Temprana en Psicosis de Cantabria (ITPCan)
Self Harm, First Episode Psychosis
Psychosocial Intervention for Suicidal Ideation in Individuals With FEP: A Feasibility Trial
To check the feasibility and acceptability of Culturally adapted Cognitive Behavioral Therapy for Psychosis (CaCBTp) and Culturally Adapted Manual Assisted Brief Psychological Intervention for Self-harm (CMAP), which we have…
- Trial name
- CMAP-FEP (NCT05728138)
- Testing
- CMAP Plus CBT
- Where
- Pakistan
- Volunteers
- 80 people
- Sponsor
- Pakistan Institute of Living and Learning
Comparing Clinical Profile and Prognosis of Schizophrenia Versus Methamphetamine Induced Psychosis, SCHIZOPHRENIA
This Hospital-based Observational Study Employed a Study Will be Conducted in Sohag University Hospital Clinics Aiming to Ensure Cases Presented With Psychosis in Two Phases to Differentiate Into Two Groups a Case of Schizophrenia or a Case of Methamphetamine Induced Psychosis.
This hospital-based observational study employed prospective follow up study will be conducted in sohag university hospital clinics aiming to ensure cases presented with psychosis in two phases to differentiate into 2 groups (a…
- Conditions
- Comparing Clinical Profile and Prognosis of Schizophrenia Versus Methamphetamine Induced Psychosis, SCHIZOPHRENIA, Methamphetamine Induced Psychosis
- Trial name
- NCT07184710
- Volunteers
- 200 people
- Sponsor
- Sohag University
First Episode Psychosis of Schizophrenia and Schizotypal Disorder, Psychotic Disorders
Extended Specialized Assertive Intervention for First Episode Psychosis
In a randomized clinical trial, the researchers want to investigate if the positive short-term outcomes (first 1-2 years), achieved with specialized assertive intervention programme (OPUS), can be maintained for five years if the…
- Conditions
- First Episode Psychosis of Schizophrenia and Schizotypal Disorder, Psychotic Disorders, Schizophrenia, Schizoaffective Disorder
- Trial name
- OPUSII (NCT00914238)
- Testing
- 2 years OPUS treatment, OPUS 5 years
- Where
- 2 sites in Denmark
- Volunteers
- 400 people
- Sponsor
- University of Copenhagen
Prodromal Schizophrenia
Neurofeedback Training for High Risk Psychosis
Young people who are at great risk for developing psychosis have cognitive deficits which are strongly related to functioning in the community.
- Trial name
- NCT03447548
- Testing
- Neurofeedback processing speed training, Active control
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Hartford Hospital
Other Immunological States or Disorders
The Potential Biomark of Serious Psychosis:a Prospective,Case-controled Study
Patients suffer from Serious Psychosis may have variation in immunological factors,BDNF and MRI.
- Trial name
- NCT02202460
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Central South University
Perioperative Psychology
Effect of Psychological Interventions on Maternal Outcomes Undergoing Cesarean
Pregnancy induced psychosis is an essential factor that influencing maternal health postpartum. When gravidas, especially nulliparas, facing labor and delivery, they will undoubtedly encounter burden from their own and…
- Trial name
- PIMAC (NCT01141010)
- Testing
- Language
- Where
- China
- Volunteers
- 365 people
- Sponsor
- Nanjing Medical University
Psychosis
Body-Mind-Spirit Intervention for Women With Early Psychosis
This is an open-labelled randomised controlled trial (RCT) that aims to examine the effectiveness of exercise coaching approach in improving the physical activity engagement in patients with psychosis.
- Trial name
- NCT03751852
- Testing
- Exercise Coaching, Psychoeducation
- Where
- Hong Kong
- Volunteers
- 57 people
- Sponsor
- The University of Hong Kong
Serious Mental Illness, Schizophrenia
Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
Patients with severe mental illness (SMI) die younger than persons in the general population. Much of the excess mortality for SMI patients is attributable to cardiovascular disease, and is exacerbated by treatment with…
- Conditions
- Serious Mental Illness, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- FITNESS (NCT02188121)
- Testing
- Simvastatin, Losartan
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Mclean Hospital
Schizophrenia, Major Depression
Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression
We investigate whether the add-on specific antitoxoplasmatic medication has positive effects in individuals with schizophrenia or major depression seropositive for Toxoplasma gondii (TG) infection.
- Trial name
- NCT00300404
- Testing
- daraprim, pyrimethamine, folinic acid
- Volunteers
- 40 people
- Sponsor
- Zentrum für Integrative Psychiatrie
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychosis, Psychosocial Functioning
Optimizing Mental Health for Young People at Clinical High Risk for Psychosis (CHR)
This proposal aims to adapt an evidence-based comprehensive psychosocial and mental health support program, the Optimal Health Program (OHP), to improve functioning, reduce distress, and build resiliency in youth who are at…
- Trial name
- NCT05757128
- Testing
- Optimal Health Program
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre for Addiction and Mental Health
Intensive Care Psychosis
Follow-up in Pediatric Intensive Care Unit
Background In developed countries, mortality rates in pediatric intensive care units (PICUs) are around 4% and thus, most children admitted to these units survive.
- Trial name
- APRELAREA (NCT06363344)
- Testing
- Questionnaires : PHQ-9 (Kroenke, 2001), the PSC (Sheldrick, 2012), the ASQ-SE (Squires, 2015), the PedsQL (Varni, 1999)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psychotic Disorders
Effects of a Peer-facilitated, Recovery-focused Self-illness Management Program for First-episode Psychosis
Psychosis is a major disabling and disruptive mental illness characterized by a wide variety of disturbances in cognition and emotions, resulting in poor psychosocial functioning and frequent relapses.
- Trial name
- Peer-RESIM (NCT06487195)
- Testing
- Peer-facilitated, Recovery-based Self-illness-management programme, Psycho-education group, Treatment-as-usual only
- Where
- Hong Kong
- Volunteers
- 198 people
- Sponsor
- Chinese University of Hong Kong
Psychosis
Effectiveness of Cognitive Remediation in a Supported Education Setting
The purpose of this study is to determine whether cognitive remediation as an adjunct to supported education, will result in improved cognitive functioning, symptoms, and performance in academic domains for persons with psychosis…
- Trial name
- NCT01492439
- Testing
- Cognitive Remediation, Supported Education
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- Centre for Addiction and Mental Health
Psychosis, Substance Use
Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study
The purpose of this study is to evaluate Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) for families experiencing early psychosis and substance use delivered exclusively or primarily via telehealth…
- Conditions
- Psychosis, Substance Use, Substance Use Disorders, Family
- Trial name
- NCT05380583
- Testing
- CRAFT-EP, TAU
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Bipolar I Disorder, Unspecified, With Psychotic Features, Bipolar I Disorder, Unspecified, Without Psychotic Features
Psychosis and Affective Research Domains and Intermediate Phenotypes
The objective of this multi-site research collaboration is to test the manifestation and distribution of biological markers for psychosis and affect dimensions across the schizophrenia/bipolar (SZ-BD) diagnostic boundary, and to…
- Trial name
- PARDIP (NCT02218853)
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Parkinson's Disease Psychosis
Expanded Access of Pimavanserin for Patients With PD Psychosis
The purpose of this program is to provide patients with PDP access to pimavanserin until the product receives marketing approval from the FDA and is commercially available.
- Trial name
- NCT02762591
- Testing
- Pimavanserin tartrate
- Sponsor
- ACADIA Pharmaceuticals Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.